Compounds > 4'-hydroxywarfarin
Page last updated: 2024-11-13

4'-hydroxywarfarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4'-hydroxywarfarin: metabolite of warfarin; RN given refers to cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54682146
CHEMBL ID149768
CHEBI ID190151
MeSH IDM0166391

Synonyms (28)

Synonym
CBDIVE_004856
NCGC00165930-01
4'-hydroxywarfarin
CHEMBL149768
2-hydroxy-3-[1-(4-hydroxyphenyl)-3-oxobutyl]-4h-chromen-4-one
4-hydroxy-3-[1-(4-hydroxyphenyl)-3-oxobutyl]chromen-2-one
4-hydroxy-3-[1-(4-hydroxyphenyl)-3-oxobutyl]-2h-chromen-2-one
24579-14-4
CHEBI:190151
3-[1-(4-hydroxyphenyl)-3-oxidanylidene-butyl]-2-oxidanyl-chromen-4-one
2-hydroxy-3-[1-(4-hydroxyphenyl)-3-oxobutyl]-1-benzopyran-4-one
A817378
4-hydroxy-3-(1-(4-hydroxyphenyl)-3-oxobutyl)-2h-1-benzopyran-2-one
2h-1-benzopyran-2-one, 4-hydroxy-3-(1-(4-hydroxyphenyl)-3-oxobutyl)-
unii-3d8g6747yq
3d8g6747yq ,
4-hydroxywarfarin
4'-hydroxy warfarin
FT-0638435
4-hydroxy-3-[1'-(4''-hydroxyphenyl)-3'-oxobutyl]-2h-1-benzopyran-2-one
AKOS030239605
J-015577
FT-0670232
4-hydroxy-3-(1-(4-hydroxyphenyl)-3-oxobutyl)-2h-chromen-2-one
(r)-4'-hydroxy warfarin
Q27257061
2-hydroxy-3-[1-(4-hydroxyphenyl)-3-oxobutyl]-4h-1-benzopyran-4-one
DTXSID80947449
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Warfarin Pathway, Pharmacokinetics82

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1133021Activity at cytochrome P450 in rat liver microsomes treated with (S)-warfarin measured after 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID16341Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16339Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16343Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID1133023Activity at cytochrome P450 in rat liver microsomes treated with (S)-warfarin measured for 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1133022Activity at cytochrome P450 in rat liver microsomes treated with (R)-warfarin measured after 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID16345Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16342Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID1133024Activity at cytochrome P450 in rat liver microsomes treated with (R)-warfarin measured for 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID16340Amount of deuterium retained was reported after normal workup in rats1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbon monoxide
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.		1.9710carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		210cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		8.2860benzenes;
hydroxycoumarin;
methyl ketone
6-hydroxywarfarin
6-hydroxywarfarin: metabolite of (R)-warfarin; RN given refers to parent cpd		2.730
7-hydroxywarfarin
7-hydroxywarfarin: a warfarin metabolite		2.730hydroxycoumarin
(S)-warfarin
(S)-warfarin : A 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one that has (S)-configuration (the racemate is warfarin, an anticoagulant drug and rodenticide).		1.95104-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one
10-hydroxywarfarin
10-hydroxywarfarin: structure given in first source		2.7330hydroxycoumarin
8-hydroxywarfarin
8-hydroxywarfarin: metabolic marker for (S)-mephenytoin hydroxylase (P4502C19); structure in first source		2.730
ConditionIndicatedRelationship StrengthStudiesTrials
Inborn Errors of Metabolism
[description not available]		02.1110
Metabolism, Inborn Errors
Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.		02.1110